In an appeal to the U.S. Drug Enforcement Administration (DEA), Food and Drug Administration (FDA) Commissioner Robert Califf recently stated there is “no reason” for the DEA to “delay” its cannabis rescheduling decision, reports suggested. However, as demonstrated by FDA Commissioner Califf’s remarks, some feel that the DEA has been taking too long to decide on this critical issue. This statement came during his testimony on Thursday before the House Oversight and Accountability Committee. The CSA divides substances into five categories called ‘Schedules.’ These Schedules are determined by their potential for abuse, medical use, and safety or potential for addiction. Schedule I substances are considered the most dangerous, with no accepted medical use and a high potential for abuse.Marijuana is currently classified as a Schedule I substance, alongside heroin, MDMA, LSD, and other hard drugs.
In an appeal to the U.S. Drug Enforcement Administration (DEA), Food and Drug Administration (FDA) Commissioner Robert Califf recently stated there is “no reason” for the DEA to “delay” its cannabis rescheduling decision, reports suggested.
This statement came during his testimony on Thursday before the House Oversight and Accountability Committee. Califf declared that he does not believe the DEA is purposefully delaying last year’s recommendation made by the U.S. Department of Health and Human Services.
Earlier in February, it was reported that some DEA officials raised concerns over the proposal to move cannabis...
Read the full article @ Marijuana Index